ProMIS Neurosciences Announces Results of Annual Meeting of Shareholders
July 02, 2021 07:30 ET
|
ProMIS Neurosciences Inc.
TORONTO and CAMBRIDGE, Mass., July 02, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
ProMIS Neurosciences congratulates Biogen on FDA accelerated approval of aducanumab for Alzheimer’s disease
June 08, 2021 07:30 ET
|
ProMIS Neurosciences Inc.
TORONTO and CAMBRIDGE, Mass., June 08, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
ProMIS Neurosciences Files Preliminary Short Form Base Shelf Prospectus
June 03, 2021 07:30 ET
|
ProMIS Neurosciences Inc.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES TORONTO and...
ProMIS Neurosciences appoints renowned scientist, Dr. David Wishart as Chief Physics Officer
May 27, 2021 07:30 ET
|
ProMIS Neurosciences Inc.
TORONTO, and CAMBRIDGE, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
ProMIS Neurosciences initiates commercialization of COVID-19 serology assay
May 25, 2021 07:30 ET
|
ProMIS Neurosciences Inc.
TORONTO and CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
ProMIS Neurosciences re-initiates path to IND for PMN310 with producer cell line development
May 21, 2021 08:30 ET
|
ProMIS Neurosciences Inc.
TORONTO and CAMBRIDGE, Mass., May 21, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
ProMIS Neurosciences appoints accomplished biotechnology executive, Neil Warma, to its Board of Directors
May 19, 2021 06:30 ET
|
ProMIS Neurosciences Inc.
TORONTO and CAMBRIDGE, Mass., May 19, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
ProMIS Neurosciences Announces First Quarter 2021 Results
May 14, 2021 07:00 ET
|
ProMIS Neurosciences Inc.
TORONTO and CAMBRIDGE, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS or the Company”), a biotechnology company focused on the discovery and...
ProMIS Neurosciences appoints renowned neuroscientist, Dr. Rudolph Tanzi, as Chair of Scientific Advisory Board
May 12, 2021 06:30 ET
|
ProMIS Neurosciences Inc.
TORONTO and CAMBRIDGE, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
ProMIS Neurosciences Announces Fiscal Year 2020 Results
March 31, 2021 07:30 ET
|
ProMIS Neurosciences Inc.
TORONTO and CAMBRIDGE, Mass., March 31, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS or the Company”), a biotechnology company focused on the discovery and...